Rigel Pharmaceuticals
RIGL
135 hedge funds and large institutions have $157M invested in Rigel Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 35 increasing their positions, 51 reducing their positions, and 34 closing their positions.
103% more call options, than puts
Call options by funds: $1.19M | Put options by funds: $584K
0.2% more ownership
Funds ownership: 7.88% → 8.09% (+0.2%)
17% less funds holding
Funds holding: 163 → 135 (-28)
31% less repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 51
61% less capital invested
Capital invested by funds: $401M → $157M (-$244M)
71% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 34
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$33M |
| 2 |
D.E. Shaw & Co
New York
|
+$5.91M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$5.07M |
| 4 |
Citigroup
New York
|
+$2.96M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$2.82M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$14.7M |
| 2 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$13.2M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$12M |
| 4 |
LCM
Laurion Capital Management
New York
|
-$9.82M |
| 5 |
Millennium Management
New York
|
-$3.76M |
RIGL Hedge Fund Activity: Q2 2022 in Review
135 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Rigel Pharmaceuticals (RIGL) for Q2 2022, worth a combined $157M — down 61% from $401M a quarter earlier.
Sellers outnumbered buyers: 34 funds closed out of RIGL and 10 opened new positions — a net loss of 24 holders — while 51 trimmed existing stakes and 35 added.
The largest buyer was State Street, adding an estimated $33M. The largest seller was Rock Springs Capital Management, exiting entirely with an estimated $14.7M sold.
- 135 institutional investors held Rigel Pharmaceuticals (RIGL) as of Q2 2022, down from 163 in Q1 2022.
- Funds reported $157M of Rigel Pharmaceuticals stock for Q2 2022, down 61% quarter-over-quarter.
- 10 funds opened new Rigel Pharmaceuticals positions in Q2 2022 and 34 closed out, a net change of -24 holders.
- The largest Rigel Pharmaceuticals buyer in Q2 2022 was State Street, an estimated $33M added.
- The largest Rigel Pharmaceuticals seller in Q2 2022 was Rock Springs Capital Management, an estimated $14.7M sold.
Based on aggregated 13F filings for Q2 2022.